Agenda

Diane is a very experienced public affairs professional whose current role is Senior Director Vaccines Public Affairs in the Global Policy & Public Affairs team at Pfizer.  Diane’s responsibilities include the adult vaccines portfolio, which includes respiratory diseases such as COVID-19, Pneumococcal Pneumonia, RSV as well as the meningococcal portfolio which has vaccines across the life course.  In addition, Diane co-chairs the IFPMA Task Force for Life Course Immunisation.  Diane represents public affairs on the International Developed Markets Vaccines Leadership Team.

Kassim Javaid studied medicine at Charing Cross and Westminster Medical School and did his house jobs in London. He then finished a three-year SHO rotation in medicine at Southampton General Hospital followed by 8 months as a registrar before starting at the MRC Environmental Epidemiology Unit in October 2000.

His research areas are in epidemiology and adult metabolic bone disease focusing vitamin D, osteoporosis, secondary fracture prevention and rare bone diseases. 

Globally experienced, energetic, results driven leader with exceptional organizational, communication, and analytical skills. Focus and experience in Healthcare industry, leading efforts in New Business Development, transformational change, program management, analytics, information technology and multidisciplinary programs.

Successful track record in creating, implementing and leading teams and solutions to transform Life Science companies, whether through new commercial approaches with customers, new business development, or enhanced internal business process management. Proven ability to guide teams through complex situations accompanied by strong business understanding across the European and United States healthcare environment.

Responsible for leading Accenture's Life Science go-to-market and analytics efforts in the Northeast USA and delivering high value to clients leveraging analytics across their business.

Specialties: Healthcare Solutions, Program Management, Transformational Change Management, New Business Development, Go to Market, B2B sales and marketing.

Dr. Manasa is a Stanford trained translational research specialist specializing in infectious diseases diagnostics and molecular epidemiology. His research work has mostly been on molecular diagnostics and pathogen genomics. He currently has active projects on HIV, Hepatitis viruses, respiratory viruses (including SAR-CoV-2) and HPV. 

He has more than 15 years international experience in molecular diagnostics and HIV drug resistance. His interests are leveraging advances in genomic technologies to provide innovative healthcare solutions in resource-limited settings. He has postdoctoral training from Stanford University in California, USA, and University of KwaZulu-Natal in Durban South Africa. He received postgraduate training fellowships from the Swiss-South African joint research program and the NIH’s Fogarty Centre as well as research and training grants from the NIH, Gilead sciences and Abbott Diagnostics. He is currently principal investigator/program director for two training grants for infectious diseases genomics and non-communicable diseases research. In addition, he leads a multidisciplinary virus discovery and molecular epidemiology research program. He has 60 peer reviewed publications in various scientific journals. 

Chad Brough is the Vice President of Healthcare Transformation at Home Instead, the world’s largest home care company headquartered in Omaha, Nebraska. In his role, Chad leads the comprehensive healthcare transformation strategy and roadmap for Home Instead’s global network that advances home care as a critical part of the healthcare ecosystem. Chad is responsible for expanding, integrating and overseeing the clinical care aspects of Home Instead’s service offerings. Chad’s thought leadership focuses on moving healthcare to the home, population health outcomes, and expanding funding sources through payor innovation and policy reform that enables aging adults to successfully age in place.

Beginning his healthcare leadership career 30 years ago, Chad has led transformational change across the healthcare continuum, from community hospitals, large health systems, academic medical centers and home care.  His expertise focuses on transforming strategic plans into operational initiatives for multi-site, complex service delivery models. Chad stands for healthcare that people value, desire and deserve.

During his career, Chad has served on the Malcolm Baldrige Board of Examiners. Currently, Chad serves on the World Economic Forum’s Edison Alliance, the Global Coalition on Aging’s Digital Health Advisory Council and Adult Vaccine Advisory Council.

 Chad earned a BA in Business Administration from Hanover College and his MBA from Indiana University.

Ms. Daniela Bas, of Italian nationality, is the Director of the Division for Inclusive Social Development at the United Nations Department of Economic and Social Affairs since May 2011. Political scientist with a major in International Politics, she graduated Magna Cum Laude with a dissertation on “The elimination of architectural barriers and the employment of people with physical disabilities”. She is also a certified journalist and worked for the major press, Radio, and Television networks and is also a certified multicultural/life coach. Ms. Bas’s interest has always been people-centred in the various activities, associations, and professional roles she has held. In addition to her work at the United Nations from 1986 to 1995, she held managerial roles until 2000 in the private sector in Italy.
 

Dr Anshu Banerjee is the Senior Advisor for WHO's Department of Reproductive Health and Research including the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP). He joined the Department in August 2015. In addition to his role as Senior Advisor to the Department, Dr Banerjee will lead WHO's work to operationalize the UN Secretary General's Global Strategy for Women’s, Children’s and Adolescents’ Health - a road map to end all preventable deaths of women, children and adolescents by 2030 and improve their health. Dr Banerjee will also work on the new Global Financing Facility (GFF) in support of the strategy.

Professor Ian Philp is the founder of Age Care Technologies (ACT) www.agecaretechnologies.org. ACT is the winner of the 2021 United Nations WSIS prize for innovation in healthy ageing for our potential to add 100 million quality life years for older people and reduce global costs of long-term care by $45 trillion.

Professor Philp is an advisor to the World Health Organisation in person-centred care for older people. He holds a Doctorate in Medicine from the University of Edinburgh and was a practicing physician for 35 years in the UK National Health Service, spending eight years an Executive Medical Director.

As Professor of Health Care for Older People at the University of Sheffield, he led teams which won the UK hospital team of the year in the care of older people and the Queen’s Anniversary Prize for Higher Education for research into improving the quality of life of older people.

From 2000-8, he was the National Clinical Director for Older People in England, leading the development and implementation of the National Service Framework for Older People, campaigning to ensure respect for dignity in care and eliminate age discrimination, leading national strategies for intermediate care, stroke, dementia and the prevention of falls and fractures.

Professor Philp was awarded a CBE in the Queen’s birthday honours in 2009 in recognition of his work to improve the lives of older people.

Thomas Hach, MD, is Executive Director Patient Engagement for Cardiovascular, Renal & Metabolism (CRM) at Novartis. He is leading end-to-end patient engagement strategy and operations for the broad CRM portfolio at Novartis. Thomas also held positions of Global Brand Medical Director Neuroscience, Senior Global Health Advisor and Director Healthcare Systems. His passion and expertise are in precision medicine, preventative medicine, patient centricity and partnerships. He joined Novartis from Boehringer Ingelheim, where he was Global Senior Medical Director, Therapeutic Area Metabolism. Prior to that, he was an associate principal at McKinsey & Company, serving as a leader in the pharmaceuticals and healthcare practice. Dr. Hach conducted several years of research and clinical practice in diabetes/microcirculation at Karolinska Institutet, Sweden. At the beginning of his clinical career, he worked in orthopedic surgery in Sweden and Germany. He received his medical degree from University of Mainz, Germany.